AU2012317325B2 - Glycosylated polypeptide and pharmaceutical composition containing same - Google Patents

Glycosylated polypeptide and pharmaceutical composition containing same Download PDF

Info

Publication number
AU2012317325B2
AU2012317325B2 AU2012317325A AU2012317325A AU2012317325B2 AU 2012317325 B2 AU2012317325 B2 AU 2012317325B2 AU 2012317325 A AU2012317325 A AU 2012317325A AU 2012317325 A AU2012317325 A AU 2012317325A AU 2012317325 B2 AU2012317325 B2 AU 2012317325B2
Authority
AU
Australia
Prior art keywords
polypeptide
fmoc
group
glycosylated
sugar chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012317325A
Other languages
English (en)
Other versions
AU2012317325A1 (en
Inventor
Kazuhiro Fukae
Yasuhiro Kajihara
Masatoshi Maeda
Izumi Sakamoto
Keisuke TAZURU
Katsunari Tezuka
Takashi Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glytech Inc
Original Assignee
Glytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Inc filed Critical Glytech Inc
Publication of AU2012317325A1 publication Critical patent/AU2012317325A1/en
Application granted granted Critical
Publication of AU2012317325B2 publication Critical patent/AU2012317325B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2012317325A 2011-10-01 2012-09-28 Glycosylated polypeptide and pharmaceutical composition containing same Ceased AU2012317325B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-218793 2011-10-01
JP2011218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
AU2012317325A1 AU2012317325A1 (en) 2014-04-17
AU2012317325B2 true AU2012317325B2 (en) 2016-10-06

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012317325A Ceased AU2012317325B2 (en) 2011-10-01 2012-09-28 Glycosylated polypeptide and pharmaceutical composition containing same

Country Status (16)

Country Link
US (1) US10358470B2 (enExample)
EP (1) EP2762489B1 (enExample)
JP (1) JP6153470B2 (enExample)
KR (1) KR101979045B1 (enExample)
CN (2) CN104080803B (enExample)
AU (1) AU2012317325B2 (enExample)
BR (1) BR112014007766B1 (enExample)
CA (1) CA2850469C (enExample)
DK (1) DK2762489T3 (enExample)
IN (1) IN2014CN02982A (enExample)
MY (1) MY168902A (enExample)
PH (1) PH12014500694B1 (enExample)
RU (1) RU2636456C2 (enExample)
SG (2) SG10201602076QA (enExample)
TW (1) TWI633115B (enExample)
WO (1) WO2013047846A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN02982A (enExample) 2011-10-01 2015-07-03 Glytech Inc
AU2014245917B2 (en) * 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
US20040115168A1 (en) * 2001-10-10 2004-06-17 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
DE69936409T2 (de) * 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
WO2001042474A2 (en) * 1999-12-08 2001-06-14 Amgen, Inc. Interferon-like molecules and uses thereof
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
PL362870A1 (en) 2001-03-15 2004-11-02 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
KR100876518B1 (ko) 2002-12-26 2008-12-31 오츠카 가가쿠 가부시키가이샤 당사슬 아스파라긴 유도체 및 그의 제조방법
WO2005019260A1 (ja) 2003-08-25 2005-03-03 Toray Industries, Inc. インターフェロンβ複合体
US20090214472A1 (en) 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
MX2007001589A (es) 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
KR100781666B1 (ko) * 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
US20080219952A1 (en) * 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
BRPI0813139A8 (pt) 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
KR101534881B1 (ko) 2007-07-31 2015-07-07 가부시키가이샤 도우사 고가쿠 겐큐쇼 펩티드의 제조방법
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
BRPI0914889A2 (pt) * 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
AU2009283678B2 (en) * 2008-08-19 2014-01-16 Glytech, Inc. Glycoprotein production method and screening method
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
JP5925760B2 (ja) 2011-03-10 2016-05-25 株式会社糖鎖工学研究所 シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド
ES2774284T3 (es) 2011-06-29 2020-07-20 Kyowa Kirin Co Ltd Método para purificar antitrombina
IN2014CN02982A (enExample) 2011-10-01 2015-07-03 Glytech Inc

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115168A1 (en) * 2001-10-10 2004-06-17 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARPUSAS, M., et al., Proc. Natl. Acad. Sci. USA, 1997, vol. 94, pages 11813-11818 *

Also Published As

Publication number Publication date
PH12014500694B1 (en) 2020-01-31
IN2014CN02982A (enExample) 2015-07-03
TW201321404A (zh) 2013-06-01
TWI633115B (zh) 2018-08-21
EP2762489B1 (en) 2018-03-28
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
US10358470B2 (en) 2019-07-23
BR112014007766A2 (pt) 2017-04-04
KR20140095051A (ko) 2014-07-31
SG11201401071YA (en) 2014-08-28
RU2636456C2 (ru) 2017-11-23
CN104080803A (zh) 2014-10-01
WO2013047846A1 (ja) 2013-04-04
EP2762489A4 (en) 2015-05-06
JP6153470B2 (ja) 2017-06-28
AU2012317325A1 (en) 2014-04-17
MY168902A (en) 2018-12-04
JPWO2013047846A1 (ja) 2015-03-30
EP2762489A9 (en) 2015-02-11
CN104080803B (zh) 2020-08-04
EP2762489A1 (en) 2014-08-06
BR112014007766B1 (pt) 2022-05-10
RU2014116550A (ru) 2015-10-27
DK2762489T3 (en) 2018-07-02
PH12014500694A1 (en) 2014-05-12
CA2850469A1 (en) 2013-04-04
US20140369964A1 (en) 2014-12-18
KR101979045B1 (ko) 2019-05-15
CN109134642A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
RU2543157C2 (ru) Гликозилированный пептид glp-1
CA2778890A1 (en) Glycosylated form of antigenic glp-1 analogue
JP5925760B2 (ja) シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド
JP6219308B2 (ja) 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法
DK2762489T3 (en) GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
US20120114595A1 (en) Sugar chain-added ailim extracellular domain and method for producing same
DK2982686T3 (en) POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired